{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:44:41Z","timestamp":1786718681832,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Indian Acad Neurol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/aian.aian_25_18","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T05:31:00Z","timestamp":1545802260000},"page":"27","source":"Crossref","is-referenced-by-count":8,"title":["Newer antiepileptic drugs discontinuation due to adverse effects: An observational study"],"prefix":"10.4103","volume":"22","author":[{"given":"Farhad","family":"Salari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Golpayegani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurosh","family":"Gharagozli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0972-2327.248505-1","first-page":"1022","volume-title":"Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample.The National Comorbidity Survey","author":"Kendler","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"key-10.4103\/0972-2327.248505-2","first-page":"g254","volume-title":"Drug treatment of epilepsy in adults","author":"Schmidt","year":"2014","journal-title":"BMJ"},{"key":"key-10.4103\/0972-2327.248505-3","first-page":"792","volume-title":"Adverse effects of antiepileptic drugs","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/0972-2327.248505-4","first-page":"S42","volume-title":"Adverse effects of antiepileptic drugs","author":"Greenwood","year":"2000","journal-title":"Epilepsia"},{"key":"key-10.4103\/0972-2327.248505-5","first-page":"885","volume-title":"Adverse effects of antiepileptic drugs: A brief overview of important issues","author":"Cramer","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"key-10.4103\/0972-2327.248505-6","first-page":"627","volume-title":"The efficacy and safety of newer anticonvulsants in patients with dementia","author":"Dolder","year":"2012","journal-title":"Drugs Aging"},{"key":"key-10.4103\/0972-2327.248505-7","first-page":"224","volume-title":"Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment","author":"Friis","year":"1993","journal-title":"Acta Neurol Scand"},{"key":"key-10.4103\/0972-2327.248505-8","first-page":"1277","volume-title":"Antiepileptics and blood dyscrasias: A cohort study","author":"Blackburn","year":"1998","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/0972-2327.248505-9","first-page":"205","volume-title":"Felbamate: Clinical and molecular aspects of a unique antiepileptic drug","author":"Brown","year":"1998","journal-title":"Crit Rev Neurobiol"},{"key":"key-10.4103\/0972-2327.248505-10","unstructured":"Haynes RB, Taylor DW, Sackett DL. Compliance in Health Care. The Johns Hopkins University Press;1979."},{"key":"key-10.4103\/0972-2327.248505-11","first-page":"29","volume-title":"The meaning of medications: Another look at compliance","author":"Conrad","year":"1985","journal-title":"Soc Sci Med"},{"key":"key-10.4103\/0972-2327.248505-12","first-page":"67","volume-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"key-10.4103\/0972-2327.248505-13","first-page":"2025","volume-title":"Severe cutaneous adverse reactions to antiepileptic drugs in Asians","author":"Yang","year":"2011","journal-title":"Neurology"},{"key":"key-10.4103\/0972-2327.248505-14","first-page":"399","volume-title":"Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions","author":"B\u0142aszczyk","year":"2013","journal-title":"Pharmacol Rep"},{"key":"key-10.4103\/0972-2327.248505-15","first-page":"451","volume-title":"A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy","author":"Christe","year":"1997","journal-title":"Epilepsy Res"},{"key":"key-10.4103\/0972-2327.248505-16","first-page":"165","volume-title":"Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy","author":"Privitera","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"key-10.4103\/0972-2327.248505-17","first-page":"173","volume-title":"Topiramate titration and tolerability","author":"Biton","year":"2001","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/0972-2327.248505-18","first-page":"1524","volume-title":"Antiepileptic drug discontinuation by people with epilepsy in the general population","author":"Giussani","year":"2017","journal-title":"Epilepsia"},{"key":"key-10.4103\/0972-2327.248505-19","first-page":"102","volume-title":"Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population","author":"Zand","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key-10.4103\/0972-2327.248505-20","first-page":"e4481","volume-title":"Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study","author":"Lai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/0972-2327.248505-21","first-page":"609","volume-title":"Subjective response to neuroleptics in schizophrenia","author":"Awad","year":"1993","journal-title":"Schizophr Bull"},{"key":"key-10.4103\/0972-2327.248505-22","first-page":"242","volume-title":"A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs","author":"Uijl","year":"2006","journal-title":"Seizure"},{"key":"key-10.4103\/0972-2327.248505-23","first-page":"1","volume-title":"Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders","author":"Awad","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key-10.4103\/0972-2327.248505-24","first-page":"408","volume-title":", et al.Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy","author":"Arif","year":"2010","journal-title":"Arch Neurol"},{"key":"key-10.4103\/0972-2327.248505-25","first-page":"859","volume-title":"The new antiepileptic drugs: A systematic review of their efficacy and tolerability","author":"Marson","year":"1997","journal-title":"Epilepsia"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:38:21Z","timestamp":1786714701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_25_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"alternative-id":["248505"],"URL":"https:\/\/doi.org\/10.4103\/aian.aian_25_18","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}